Indefinite Delivery Contract HHSN261201300034I

The Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) has awarded a single-award indefinite delivery contract to Polypeptide Laboratories San Diego, LLC, a Contract Development & Manufacturing Organization (CDMO), to provide chemistry, manufacturing, and controls (CMC) services for the development of drug substances. This five-year, $49.7 million IDV contract, awarded without set-asides, supports NCATS'...

The Department of Health and Human Services Food and Drug Administration awarded an indefinite delivery contract to We Pharma, Inc., doing business as WEP Clinical, with a potential value of $9.5 million. The contract has no set-aside designation and is a single-award arrangement to provide currently marketed drug products for FDA research studies from September 2020 through September 2025. Under this contract, WEP Clinical has received multiple firm fixed price delivery orders to supply...

Altasciences Clinical Kansas Inc. was awarded a single-award indefinite delivery contract from the Department of Health and Human Services Food and Drug Administration valued at up to $5 million. The contract aims to advance generic drug approvals through the conduct of bioequivalence studies and characterization of generic drugs. Three firm fixed price delivery orders have been issued against this contract to date, with places of performance in Overland Park, Kansas. The first delivery order,...

The U.S. National Center for Advancing Translational Sciences (NCATS) has awarded an indefinite delivery contract (IDC) with a ceiling value of $49,885,703.00 to Purdue University to provide Chemistry, Manufacturing, and Control (CMC) services for the development of drug products. This multiple-award contract has an ultimate completion date of July 31, 2031. The scope of the contract includes a broad range of preclinical services required for the design, development, manufacture, and release...

This is an indefinite-delivery/indefinite-quantity (IDIQ) contract awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences (NCATS) to Bachem Americas, Inc., a foreign-owned, for-profit manufacturer of pharmaceutical ingredients. The contract, valued up to $49.7M, is for Chemistry, Manufacturing, and Controls (CMC) services to support NCATS' drug development programs, including the production of active...

The subject federal contract IDV award is a $4,999,999.00 single-award Indefinite Delivery Contract (IDC) held by Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract was awarded on April 29, 2015 by the Defense Logistics Agency (DLA) Troop Support Medical and runs through December 31, 2025. This IDC serves as a primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs...

This Indefinite Delivery Contract (IDC) was awarded by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor, Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract has a ceiling value of $4,999,999.00 and a period of performance running through December 25, 2024. The contract is for the delivery of a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other...

The Department of Health and Human Services National Institutes of Health (NIH) Clinical Center has awarded a $6 million, single-award Indefinite Delivery Contract (IDC) to Central Admixture Pharmacy Services Inc. (Caps) for the provision of 503A compounded sterile preparations and parenteral nutrition solutions. Caps is a for-profit organization that operates as both a 503A traditional pharmacy and a 503B outsourcing facility, specializing in customized intravenous mixtures, sterile admixtures,...

This indefinite delivery contract awarded by the National Institute on Drug Abuse (NIDA), a civilian federal agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific, provides regulatory consulting assistance and research and development support for medical device development projects under the Blueprint MedTech (BPMT) program. The contract has a ceiling value of $24 million over a 5-year ordering period from September 2022 to...

This $49.9 million Indefinite Delivery Contract was awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to PPD Development LP, a global contract research organization (CRO) subsidiary of Thermo Fisher Scientific. The contract is for research and development related to clinical studies under NIDA's Blueprint MedTech program, which focuses on medical technology development for nervous system disorders. Under this IDC, PPD will provide a range of services including developing...